announced today that has the United States Food and Drug Administration approved for granted Prevnar 13 , the Company’s 13-valent pneumococcal conjugate vaccine. Prevnar 13 is indicated for active immunization of children 6 weeks to 5 years for the prevention of invasive disease by 13 Streptococcus pneumoniae serotypes 1, 14 caused, displayed, 19F and 23F. Prevnar 13 is also indicated for the prevention of otitis media by serotypes 4, causing 19F and 23F. No otitis media efficacy data for serotypes 1, 7F and 19A available.

As with any vaccine, Prevnar may not all individuals receiving the vaccine from serious invasive disease caused by S. Pneumoniae. This vaccine should not be used for treatment of acute infection.Important Safety Information for Prevnarincluded in clinical trials, the most commonly reported adverse reactions at the injection site, fever (38 C/100 irritability, drowsiness, restless sleep, decreased appetite, vomiting, diarrhea and rash. – risks associated with all vaccines, including Prevnar hypersensitivity to any vaccine component, including diphtheria toxoid, is a contraindication to its use Prevnar does not protect 100 % of children vaccinated immunization not with Prevnar for routine diphtheria immunization.Investigators hope that to confirm the clinical findings in in a second study having a prospective assembled population of patients, ideally of a cooperative group and another multi-institutional study. HistoRx pleased to to see for this application data confirm our efforts in the production an objective, quantitative and reproducible measurement of the IT to samples, commented Jason Christiansen, Senior Director of Operations for HistoRx and another author of the paper. We were excited, additional knowledge about recurrence of disease irradiation of irradiation have an answer, and will address the appropriate examinations in order to confirm it.